logo

Conatus Pharmaceuticals Inc (CNAT)



Trade CNAT now with
  Date
  Headline
12/5/2018 7:34:07 AM Conatus Says Primary Endpoint Not Met In ENCORE-PH Phase 2b Clinical Trial In NASH Cirrhosis
7/2/2018 7:34:10 AM Conatus Pharma Announces Publication Of Results From Preclinical Studies Of Pan-caspase Inhibitor Emricasan
4/30/2018 7:34:51 AM Conatus Completes Enrollment In ENCORE-PH Phase 2b Clinical Trial
4/18/2018 7:32:39 AM Conatus Pharma Says IDN-7314 Pan-caspase Inhibitor Reduces Hepatic Tissue Factor-Driven Coagulation In Vitro And In Vivo
4/9/2018 7:35:33 AM Conatus Pharma Says Pan-caspase Inhibitor IDN-7314 Reduces Inflammation And Liver Injury In Mouse Model Of PSC
4/4/2018 4:13:41 PM Conatus Pharmaceuticals Announces Top-line Results From Phase 2b POLT-HCV-SVR Clinical Trial
4/4/2018 4:11:37 PM Conatus Pharmaceuticals ; Trading Expected To Resume At 4:35 PM ET
4/4/2018 4:02:38 PM Conatus Pharmaceuticals ; Trading Halt Pending News